{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:24:03Z","timestamp":1791239043892,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,6,8]],"date-time":"2010-06-08T00:00:00Z","timestamp":1275955200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s11904-010-0052-6","type":"journal-article","created":{"date-parts":[[2010,6,7]],"date-time":"2010-06-07T05:55:44Z","timestamp":1275890144000},"page":"134-142","source":"Crossref","is-referenced-by-count":23,"title":["Management of Cryptococcal Meningitis in Sub-Saharan Africa"],"prefix":"10.1007","volume":"7","author":[{"given":"Arthur","family":"Jackson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina C.","family":"Hosseinipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,8]]},"reference":[{"key":"52_CR1","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ije\/27.4.698","volume":"4","author":"M Okongo","year":"1998","unstructured":"Okongo M, Morgan D, Mayanja B, et al.: Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. Int J Epidemiol 1998, 4:698\u2013702.","journal-title":"Int J Epidemiol"},{"key":"52_CR2","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/00002030-200205030-00009","volume":"16","author":"N French","year":"2002","unstructured":"French N, Gray K, Watera C, et al.: Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002, 16:1031\u20131038.","journal-title":"AIDS"},{"key":"52_CR3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","volume":"23","author":"BJ Park","year":"2009","unstructured":"\u2022 Park BJ, Wannemuehler KA, Marston BJ, et al.: Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS. AIDS 2009, 23:525\u2013530. This article highlights the devastating effect of this underappreciated disease in resource-limited areas.","journal-title":"AIDS"},{"key":"52_CR4","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/0140-6736(90)92283-N","volume":"336","author":"DH Ellis","year":"1990","unstructured":"Ellis DH, Pfeiffer TJ: Ecology, life cycle, and infectious propagule of Cryptococcus neoformans. Lancet 1990, 336:923\u2013925.","journal-title":"Lancet"},{"key":"52_CR5","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1542\/peds.107.5.e66","volume":"107","author":"DL Goldman","year":"2001","unstructured":"Goldman DL, Khine H, Abadi J, et al.: Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 2001, 107:E66.","journal-title":"Pediatrics"},{"key":"52_CR6","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/INF.0b013e318047e073","volume":"26","author":"J Davis","year":"2007","unstructured":"Davis J, Zheng WY, Glatman-Freedman A, et al.: Serologic evidence for regional differences in pediatric cryptococcal infection. Pediatr Infect Dis J 2007, 26:549\u2013551.","journal-title":"Pediatr Infect Dis J"},{"key":"52_CR7","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa065711","volume":"357","author":"M Scarborough","year":"2007","unstructured":"Scarborough M, Gordon SB, Whitty CJ, et al.: Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J Med 2007, 357:2441\u20132450.","journal-title":"N Engl J Med"},{"key":"52_CR8","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/604716","volume":"49","author":"T Bicanic","year":"2009","unstructured":"\u2022\u2022 Bicanic T, Muzoora C, Brouwer AE, et al.: Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009, 49:702\u2013709. This article validates a useful tool for assessing efficacy of anticryptococcal regimens.","journal-title":"Clin Infect Dis"},{"key":"52_CR9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1086\/313603","volume":"30","author":"JR Graybill","year":"2000","unstructured":"Graybill JR, Sobel J, Saag M, et al.: Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000, 30:47\u201354.","journal-title":"Clin Infect Dis"},{"key":"52_CR10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM199707033370103","volume":"337","author":"CM Horst van der","year":"1997","unstructured":"van der Horst CM, Saag MS, Cloud GA, et al.: Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997, 337:15\u201321.","journal-title":"N Engl J Med"},{"key":"52_CR11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0163-4453(94)94161-0","volume":"28","author":"D Maher","year":"1994","unstructured":"Maher D, Mwandumba H: Cryptococcal meningitis in Lilongwe and Blantyre, Malawi. J Infect 1994, 28:59\u201364.","journal-title":"J Infect"},{"key":"52_CR12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1086\/515074","volume":"28","author":"PA Robinson","year":"1999","unstructured":"Robinson PA, Bauer M, Leal MA, et al.: Early mycological treatment failure in AIDS-associated cryptococcal meningitis. Clin Infect Dis 1999, 28:82\u201392.","journal-title":"Clin Infect Dis"},{"key":"52_CR13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","volume":"50","author":"JR Perfect","year":"2010","unstructured":"Perfect JR, Dismukes WE, Dromer F, et al.: Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010, 50:291\u2013322.","journal-title":"Clin Infect Dis"},{"key":"52_CR14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1086\/518607","volume":"45","author":"T Bicanic","year":"2007","unstructured":"\u2022 Bicanic T, Meintjes G, Wood R, et al.: Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007, 45:76\u201380. This article supports the use of AmB when possible for CM and highlights the fact that lower doses of fluconazole are very ineffective at clearing disease.","journal-title":"Clin Infect Dis"},{"key":"52_CR15","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/pgmj.77.914.769","volume":"77","author":"P Mwaba","year":"2001","unstructured":"Mwaba P, Mwansa J, Chintu C, et al.: Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J 2001, 77:769\u2013773.","journal-title":"Postgrad Med J"},{"key":"52_CR16","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/507895","volume":"43","author":"T Bicanic","year":"2006","unstructured":"Bicanic T, Harrison T, Niepieklo A, et al.: Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006, 43:1069\u20131073.","journal-title":"Clin Infect Dis"},{"key":"52_CR17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1086\/588792","volume":"47","author":"T Bicanic","year":"2008","unstructured":"Bicanic T, Wood R, Meintjes G, et al.: High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008, 47:123\u2013130.","journal-title":"Clin Infect Dis"},{"key":"52_CR18","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(04)16301-0","volume":"363","author":"AE Brouwer","year":"2004","unstructured":"Brouwer AE, Rajanuwong A, Chierakul W, et al.: Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004, 363:1764\u20131767.","journal-title":"Lancet"},{"key":"52_CR19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1086\/649861","volume":"50","author":"JC Nussbaum","year":"2010","unstructured":"\u2022\u2022 Nussbaum JC, Jackson A, Namarika D, et al.: Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis 2010, 50:338\u2013344. This article shows the most effective combination of oral therapies for CM to date, with EFA of fluconazole 1200 mg\/day plus flucytosine approaching that of AmB alone. It lends weight to the call for flucytosine to be made available in resource-limited settings.","journal-title":"Clin Infect Dis"},{"key":"52_CR20","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1371\/journal.pmed.0040021","volume":"4","author":"F Dromer","year":"2007","unstructured":"Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O: Determinants of disease presentation and outcome during cryptococcosis: the CryptoA\/D study. PLoS Med 2007, 4:e21.","journal-title":"PLoS Med"},{"key":"52_CR21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/13693780701851695","volume":"46","author":"E Milefchik","year":"2008","unstructured":"\u2022 Milefchik E, Leal MA, Haubrich R, et al.: Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol 2008, 46:393\u2013395. This article supports the use of high-dose fluconazole with flucytosine.","journal-title":"Med Mycol"},{"key":"52_CR22","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1086\/593194","volume":"47","author":"N Longley","year":"2008","unstructured":"\u2022 Longley N, Muzoora C, Taseera K, et al.: Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 2008, 47:1556\u20131561. This article demonstrates the safety and efficacy of higher doses of fluconazole.","journal-title":"Clin Infect Dis"},{"key":"52_CR23","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1086\/599112","volume":"48","author":"PG Pappas","year":"2009","unstructured":"\u2022 Pappas PG, Chetchotisakd P, Larsen RA, et al.: A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis 2009, 48:1775\u20131783. This study shows improved efficacy of AmB combined with fluconazole 800 mg over AmB alone.","journal-title":"Clin Infect Dis"},{"key":"52_CR24","first-page":"CD005647","volume":"4","author":"D Sloan","year":"2008","unstructured":"Sloan D, Dlamini S, Paul N, Dedicoat M: Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings. Cochrane Database Syst Rev 2008, 4:CD005647.","journal-title":"Cochrane Database Syst Rev"},{"key":"52_CR25","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/j.1552-4604.1991.tb03718.x","volume":"31","author":"G Apseloff","year":"1991","unstructured":"Apseloff G, Hilligoss DM, Gardner MJ, et al.: Induction of fluconazole metabolism by rifampin: in vivo study in humans. J Clin Pharmacol 1991, 31:358\u2013361.","journal-title":"J Clin Pharmacol"},{"key":"52_CR26","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJM199102283240902","volume":"324","author":"SA Bozzette","year":"1991","unstructured":"Bozzette SA, Larsen RA, Chiu J, et al.: A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1991, 324:580\u2013584.","journal-title":"N Engl J Med"},{"key":"52_CR27","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJM199203193261203","volume":"326","author":"WG Powderly","year":"1992","unstructured":"Powderly WG, Saag MS, Cloud GA, et al.: A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med 1992, 326:793\u2013798.","journal-title":"N Engl J Med"},{"key":"52_CR28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/515110","volume":"28","author":"MS Saag","year":"1999","unstructured":"Saag MS, Cloud GA, Graybill JR, et al.: A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999, 28:291\u2013296.","journal-title":"Clin Infect Dis"},{"key":"52_CR29","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1086\/374849","volume":"36","author":"A Vibhagool","year":"2003","unstructured":"Vibhagool A, Sungkanuparph S, Mootsikapun P, et al.: Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis 2003, 36:1329\u20131331.","journal-title":"Clin Infect Dis"},{"key":"52_CR30","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1086\/339680","volume":"185","author":"JA Aberg","year":"2002","unstructured":"Aberg JA, Price RW, Heeren DM, Bredt B: A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapy. J Infect Dis 2002, 185:1179\u20131782.","journal-title":"J Infect Dis"},{"key":"52_CR31","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/QAD.0b013e32832605fe","volume":"23","author":"T Bicanic","year":"2009","unstructured":"Bicanic T, Brouwer AE, Meintjes G, et al.: Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS 2009, 23:701\u2013706.","journal-title":"AIDS"},{"key":"52_CR32","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/QAD.0b013e328333c005","volume":"24","author":"A Loyse","year":"2010","unstructured":"Loyse A, Wainwright H, Jarvis JN, et al.: Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. AIDS 2010, 24:405\u2013410.","journal-title":"AIDS"},{"key":"52_CR33","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1258\/ijsa.2007.007286","volume":"19","author":"W Manosuthi","year":"2008","unstructured":"Manosuthi W, Sungkanuparph S, Chottanapund S, et al.: Temporary external lumbar drainage for reducing elevated intracranial pressure in HIV-infected patients with cryptococcal meningitis. Int J STD AIDS 2008, 19:268\u2013271.","journal-title":"Int J STD AIDS"},{"key":"52_CR34","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1086\/515161","volume":"28","author":"MK Park","year":"1999","unstructured":"Park MK, Hospenthal DR, Bennett JE: Treatment of hydrocephalus secondary to cryptococcal meningitis by use of shunting. Clin Infect Dis 1999, 28:629\u2013633.","journal-title":"Clin Infect Dis"},{"key":"52_CR35","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1086\/342299","volume":"35","author":"PN Newton","year":"2002","unstructured":"Newton PN, Thai le H, Tip NQ, et al.: A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis 2002, 35:769\u2013772.","journal-title":"Clin Infect Dis"},{"key":"52_CR36","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/QAI.0b013e318183181e","volume":"49","author":"GP Bisson","year":"2008","unstructured":"Bisson GP, Nthobatsong R, Thakur R, et al.: The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana. J Acquir Immune Defic Syndr 2008, 49:227\u2013229.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"52_CR37","doi-asserted-by":"crossref","first-page":"e5575","DOI":"10.1371\/journal.pone.0005575","volume":"4","author":"A Zolopa","year":"2009","unstructured":"Zolopa A, Andersen J, Powderly W, et al.: Early antiretroviral therapy reduces AIDS progression\/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009, 4:e5575.","journal-title":"PLoS One"},{"key":"52_CR38","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1086\/652652","volume":"50","author":"A Makadzange","year":"2010","unstructured":"Makadzange A, Ndhlovu CE, Takarinda K, et al.: Early vs delayed initation of antiretroviral therapy for concurrent HIV infection and cryptococcal meningitis in sub-saharan Africa. Clin Infect Dis 2010, 50:1532\u20131538.","journal-title":"Clin Infect Dis"},{"key":"52_CR39","doi-asserted-by":"crossref","unstructured":"McCarthy K, Meintjes G: Guidelines for the prevention, diagnosis and management of cryptococcal meningitis and disseminated cryptococcosis in HIV-infected patients. Southern African J HIV Med 2007, 25\u201335.","DOI":"10.4102\/sajhivmed.v8i3.617"},{"key":"52_CR40","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1093\/jac\/dkp451","volume":"65","author":"K Wakeham","year":"2010","unstructured":"Wakeham K, Parkes-Ratanshi R, Watson V, et al.: Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans. J Antimicrob Chemother 2010, 65:316\u2013319.","journal-title":"J Antimicrob Chemother"},{"key":"52_CR41","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2334-7-14","volume":"7","author":"W Manosuthi","year":"2007","unstructured":"Manosuthi W, Athichathanabadi C, Uttayamakul S, et al.: Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. BMC Infect Dis 2007, 7:14.","journal-title":"BMC Infect Dis"},{"key":"52_CR42","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/QAI.0b013e3181a56f2e","volume":"51","author":"T Bicanic","year":"2009","unstructured":"Bicanic T, Meintjes G, Rebe K, et al.: Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 2009, 51:130\u2013134.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"52_CR43","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/01.aids.0000174450.70874.30","volume":"19","author":"O Lortholary","year":"2005","unstructured":"Lortholary O, Fontanet A, Memain N, et al.: Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005, 19:1043\u20131049.","journal-title":"AIDS"},{"key":"52_CR44","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1056\/NEJM199503163321102","volume":"332","author":"WG Powderly","year":"1995","unstructured":"Powderly WG, Finkelstein D, Feinberg J, et al.: A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med 1995, 332:700\u2013705.","journal-title":"N Engl J Med"},{"key":"52_CR45","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1086\/338154","volume":"34","author":"S Chariyalertsak","year":"2002","unstructured":"Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE: A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002, 34:277\u2013284.","journal-title":"Clin Infect Dis"},{"key":"52_CR46","unstructured":"Essential Prevention and Care Interventions for Adults and Adolescents Living With HIV in Resource-Limited Settings. World Health Organization; 2008."},{"key":"52_CR47","unstructured":"Parkes-Ratanshi R, Kamali A, Wakeham K, et al.: Successful primary prevention of cryptococcal meningitis using fluconazole prophylaxis in HIV-infected Ugandan adults [abstract]. Conference on Retroviruses and Opportunistic Infections. 2009, In press."},{"key":"52_CR48","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/j.1365-3156.2007.01874.x","volume":"12","author":"CA Liechty","year":"2007","unstructured":"Liechty CA, Solberg P, Were W, et al.: Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007, 12:929\u2013935.","journal-title":"Trop Med Int Health"},{"key":"52_CR49","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1086\/597262","volume":"48","author":"JN Jarvis","year":"2009","unstructured":"\u2022\u2022 Jarvis JN, Lawn SD, Vogt M, et al.: Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009, 48:856\u2013862. This study suggests an approach to reduce the incidence of clincial CM in resource-limited settings by screening for CrAg in at-risk individuals.","journal-title":"Clin Infect Dis"},{"key":"52_CR50","volume-title":"Serum cryptococcal antigen (CRAG) screening: Cost-effective method to prevent death in HIV-infected persons with CD4 \u2264100\/\u03bcL in sub-Saharan Africa","author":"DB Meya","year":"2009","unstructured":"\u2022\u2022 Meya DB, Castelnuovo B, Kambugu A, et al.: Serum cryptococcal antigen (CRAG) screening: Cost-effective method to prevent death in HIV-infected persons with CD4 \u2264100\/\u03bcL in sub-Saharan Africa. Cape Town, South Africa: International AIDS Society; 2009. This study shows the cost-benefit implications of a CrAg screening approach in resource-limited settings. It is shown to be a cost-effective method."}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-010-0052-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11904-010-0052-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-010-0052-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T01:08:38Z","timestamp":1635469718000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11904-010-0052-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,8]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["52"],"URL":"https:\/\/doi.org\/10.1007\/s11904-010-0052-6","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,8]]}}}